Experts
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on ResMed.
RELATED STOCKHEAD STORIES
Experts
ScoPo’s powerplays: Bullish on mobile X-ray company Micro-X
News
ScoPo’s powerplays: Morgans’ healthcare picks for 2021
News
The best asset class in 2021 could be one that’s been ignored for ‘nearly a decade’
Experts
Scopo’s powerplays: Feeling bullish for end of 2020
Experts
Scopo’s Health Powerplays: Show me the (grant) money
News
What ASX investors should look for in a COVID-19 earnings season
Experts
Scopo’s powerplays: Strap yourselves in for some M&A
News
‘Dividend recession’ heading for the Australian market
Health & Biotech
COVID-19 adds $9bn to top four ASX health stocks
News
Kick Back: The 10 biggest stories you might have missed on Stockhead this week
Health & Biotech
Greens push for permanent telehealth funding
Health & Biotech
The healthcare winners and losers after COVID-19, and what comes next
Health & Biotech
We’re still here: investors keen on health despite market shun
Experts
Scopo’s health powerplays: Markets be crazy, buy the dip
Experts
ScoPo’s health powerplays: The transition to greatest
Health & Biotech
Dr Boreham’s Crucible: A simpler device gives Atomo the upper hand in blood-based diagnostics
Experts